As big pharma has tightened the purse strings for technology spending, proteomics companies who rely on research deals for revenues had to make cuts — including MDS Proteomics. But there is a silver lining on the horizon: MDSP is expecting to sign a deal with a large pharmaceutical company “within 4 to 6 weeks,” and has initiated three pilot projects with pharmaceutical companies that bring in some revenue, according to Anil Amlani, MDSP’s CFO.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.